Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin-Angiotensin-Aldosterone System

F. Simko, T. Baka, P. Stanko, K. Repova, K. Krajcirovicova, S. Aziriova, O. Domenig, S. Zorad, M. Adamcova, L. Paulis

. 2022 ; 10 (8) : . [pub] 20220731

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22023624

Grant support
1/0035/19 VEGA
20-0421 APVV

This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether this potential protection is associated with RAAS alterations. Five groups of three-month-old male Wistar rats and SHRs were treated for six weeks as follows: untreated Wistar controls, Wistar plus sacubitril/valsartan, SHR, SHR plus sacubitril/valsartan, and SHR plus ivabradine. The SHRs developed a systolic blood pressure (SBP) increase, LV hypertrophy and fibrosis, and LV systolic and diastolic dysfunction. However, no changes in serum RAAS were observed in SHRs compared with the controls. Elevated SBP in SHRs was decreased by sacubitril/valsartan but not by ivabradine, and only sacubitril/valsartan attenuated LV hypertrophy. Both sacubitril/valsartan and ivabradine reduced LV collagen content and attenuated LV systolic and diastolic dysfunction. Sacubitril/valsartan increased the serum levels of angiotensin (Ang) II, Ang III, Ang IV, Ang 1-5, Ang 1-7, and aldosterone, while ivabradine did not affect the RAAS. We conclude that the SHR is a normal-to-low serum RAAS model of experimental hypertension. While the protection of the hypertensive heart in SHRs by sacubitril/valsartan may be related to an Ang II blockade and the protective Ang 1-7, the benefits of ivabradine were not associated with RAAS modulation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023624
003      
CZ-PrNML
005      
20231121101958.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines10081844 $2 doi
035    __
$a (PubMed)36009391
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia $u 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, 83305 Bratislava, Slovakia $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia $1 0000000299224885
245    10
$a Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin-Angiotensin-Aldosterone System / $c F. Simko, T. Baka, P. Stanko, K. Repova, K. Krajcirovicova, S. Aziriova, O. Domenig, S. Zorad, M. Adamcova, L. Paulis
520    9_
$a This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether this potential protection is associated with RAAS alterations. Five groups of three-month-old male Wistar rats and SHRs were treated for six weeks as follows: untreated Wistar controls, Wistar plus sacubitril/valsartan, SHR, SHR plus sacubitril/valsartan, and SHR plus ivabradine. The SHRs developed a systolic blood pressure (SBP) increase, LV hypertrophy and fibrosis, and LV systolic and diastolic dysfunction. However, no changes in serum RAAS were observed in SHRs compared with the controls. Elevated SBP in SHRs was decreased by sacubitril/valsartan but not by ivabradine, and only sacubitril/valsartan attenuated LV hypertrophy. Both sacubitril/valsartan and ivabradine reduced LV collagen content and attenuated LV systolic and diastolic dysfunction. Sacubitril/valsartan increased the serum levels of angiotensin (Ang) II, Ang III, Ang IV, Ang 1-5, Ang 1-7, and aldosterone, while ivabradine did not affect the RAAS. We conclude that the SHR is a normal-to-low serum RAAS model of experimental hypertension. While the protection of the hypertensive heart in SHRs by sacubitril/valsartan may be related to an Ang II blockade and the protective Ang 1-7, the benefits of ivabradine were not associated with RAAS modulation.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baka, Tomas $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia $1 0000000347529828
700    1_
$a Stanko, Peter $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia
700    1_
$a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia $1 0000000272351710
700    1_
$a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia
700    1_
$a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia
700    1_
$a Domenig, Oliver $u Attoquant Diagnostics, 1110 Vienna, Austria
700    1_
$a Zorad, Štefan, $d 1956- $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia $7 xx0310348
700    1_
$a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, 50003 Hradec Kralove, Czech Republic $1 0000000333209735
700    1_
$a Paulis, Ludovit $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, 81371 Bratislava, Slovakia
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36009391 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20231121101956 $b ABA008
999    __
$a ind $b bmc $g 1853949 $s 1174912
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c 8 $e 20220731 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
GRA    __
$a 1/0035/19 $p VEGA
GRA    __
$a 20-0421 $p APVV
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Archiving options